SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.
© Tetiana Yurchenko/Shutterstock.com
ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
Renal Effects: SGLT2 Inhibitors in Type 2 Diabetes
A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.
Interesting T2DM: Pharmacotherapy & Obesity Outcomes
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
Dapagliflozin: All-Cause & Cardiovascular Mortality
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
Interesting T2DM: Peds Obesity & AHA Guides
Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.
UTI Risk by Type of SGLT2 Inhibitor
The risk of urinary tract infections (UTIs), but not necessarily genital infections, may vary by agent within the SGLT2 inhibitor class.
Interesting T2DM: Neuropathy Care & Oral Tx Update
Our January list includes new care guidelines for neuropathy, updates to oral medication recommendations, and long-term RYGB outcomes for adolescents.
By clicking Accept, you agree to become a member of the UBM Medica Community.